1.        Crohn's and Colitis UK.


1.        Parray FQ, Wani ML, Bijli AH, Thakur N, Irshad I, Nayeem-ul-Hassan. Crohn’s Disease: A Surgeon’s Perspective. Saudi J Gastroenterol. 2011;17(1):6-15. doi:10.4103/1319-3767.74430.

2.        Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence ofCrohn’s disease. Clin Gastroenterol Hepatol. 2010;8(7):591-599. doi:10.1016/j.cgh.2010.01.016.

3.        Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121(5):1080-1087.

4.        Rutgeerts P. Crohn’s disease recurrence can be prevented after ileal resection. Gut . 2002;51 (2 ):152-153. doi:10.1136/gut.51.2.152 .

5.        Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EVJ. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19(9):2001-2010. doi:10.1097/MIB.0b013e318281f3bb.

6.        Allina J, Stanca CM, Garber J, et al. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun. 2008;30(4):238-245. doi:S0896-8411(07)00119-9 [pii]10.1016/j.jaut.2007.10.003.

7.        Helavirta I, Huhtala H, Hyöty M, Collin P, Aitola P. Restorative proctocolectomy for ulcerative colitis IN 1985–2009. Scand J Surg . June 2015. doi:10.1177/1457496915590540 .

8.        fact-sheet-about-surgery-for @ Fact Sheet--About Surgery for IBD.

9.        Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn’s disease. World J Gastroenterol. 2014;20(5):1147-1154. doi:10.3748/wjg.v20.i5.1147.

10.     Hashash JG, Regueiro M. A Practical Approach to Preventing Postoperative Recurrence in Crohn’s Disease. Curr Gastroenterol Rep. 2016;18(5):1-6. doi:10.1007/s11894-016-0499-8.

11. Nursing Care Plans. Available at:

12. Saibil, F. (2011). Crohn’s Disease and Ulcerative Colitis: Everything You Need To Know - The Complete Practical Guide. Firefly Books.

13. Geltzeiler, C. B., Young, J. I., Diggs, B. S., Keyashian, K., Deveney, K., Lu, K. C., … Herzig, D. O. (2015). Strictureplasty for Treatment of Crohn’s Disease: an ACS-NSQIP Database Analysis. Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract, 19(5), 905–910.

14. Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(35):7868-7881. doi:10.3748/wjg.v22.i35.7868.

15. Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. International Journal of Clinical and Experimental Medicine. 2015;8(12):22529-22542.

16. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315(8167):514.

17. Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(35):7868-7881. doi:10.3748/wjg.v22.i35.7868.

18. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn’s disease clinical course and severity in obese patients. Clin Nutr. 2002;21:51–57.

19. Mahé E, Beauchet A, Bodemer C, Phan A, Bursztejn AC, Boralevi F, Souillet AL, Chiaverini C, Bourrat E, Miquel J, et al. Psoriasis and obesity in French children: a case-control, multicentre study. Br J Dermatol. 2015;172:1593–1600.

20. Bhalme M, Sharma A, Keld R, Willert R, Campbell S. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol. 2013;25:543–549.

21. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504–514.

22. Brown RA, Spina D, Butt S, Summers GD. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol. 2012;31:455–461.

23. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:482–488.

24. Connelly TM, Juza RM, Sangster W, Sehgal R, Tappouni RF, Messaris E. Volumetric fat ratio and not body mass index is predictive of ileocolectomy outcomes in Crohn’s disease patients. Dig Surg. 2014;31:219–224.

25. Ding Z, Wu XR, Remer EM, Lian L, Stocchi L, Li Y, McCullough A, Remzi FH, Shen B. Association between high visceral fat area and postoperative complications in patients with Crohn’s disease following primary surgery. Colorectal Dis. 2016;18:163–172.

26. Klare P, Nigg J, Nold J, Haller B, Krug AB, Mair S, Thoeringer CK, Christle JW, Schmid RM, Halle M, et al. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. Digestion. 2015;91:239–247.

27. Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, Hansen PR, Astrup A, Skov L. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149:795–801.

28. Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, Veneziano L, Pellacani G. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014;170:634–642.

29. Stidham RW, Waljee AK, Day NM, Bergmans CL, Zahn KM, Higgins PD, Wang SC, Su GL. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn’s disease. Inflamm Bowel Dis. 2015;21:1306–1313.

30. Bilski J, Mazur-Bialy AI, Wierdak M, Brzozowski T. The impact of physical activity and nutrition on inflammatory bowel disease: the potential role of cross talk between adipose tissue and skeletal muscle. J Physiol Pharmacol. 2013;64:143–155.

31. Ahmed W, Katz S. Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2016;12(11):668-679.

32. Supplement: Effects of Probiotics and Prebiotics. Sheil B, Shanahan F, O'Mahony L. Probiotic Effects on Inflammatory Bowel DiseaseJ. Nutr. March 2007 137: 3 819S-824S.

33. The impact of inflammatory bowel disease in Canada. 2012 Final Report and Recommendations.

34. Lee J. Fecal Calprotectin in Inflammatory Bowel Disease. Korean J Gastroenterol. 2016 May 25;67(5):233-7. doi: 10.4166/kjg.2016.67.5.233.